Literature DB >> 16499663

The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.

Haakon Skogseth1, Erik Larsson, Jostein Halgunset.   

Abstract

Proteolytic enzymes, and especially urokinase plasminogen activator (uPA), play an important role in tumour invasion and metastasis. Previously we demonstrated that the production of urokinase plasminogen activator (uPA) was decreased by several tyrosine kinase inhibitors (TKI) in two prostatic carcinoma cell lines. The effect of the two TKI genistein and tyrphostin AG-1478 was investigated in the prostate carcinoma cell lines PC-3 and DU-145. A reconstituted basal lamina (Matrigel) was used as a migration barrier. The production of matrix metalloproteinases (MMP) was also measured. Roles of plasminogen and uPA were examined. Cell invasion was increased by plasminogen, but this enhanced cell migration was counteracted by TKI treatment. The increased cell invasion induced by plasminogen was decreased by at least 60% in both cell lines when alpha-2 anti-plasmin was added to the assay. Cells in the absence of plasminogen were not affected by TKI. External uPA failed to regenerate the decreased cell invasion caused by TKI. The production of MMP was inhibited by both TKI. Our results indicate a possible role of TKI as inhibitors of cancer cell invasion by inhibiting uPA and MMP production.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16499663     DOI: 10.1111/j.1600-0463.2006.apm_230.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

1.  Design, Synthesis, and Evaluation of Genistein Analogues as Anti-Cancer Agents.

Authors:  Pahoua Xiong; Rubing Wang; Xiaojie Zhang; Eduardo DeLa Torre; Francisco Leon; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

2.  Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.

Authors:  Nagi Kumar; Theresa Crocker; Tiffany Smith; Julio Pow-Sang; Philippe E Spiess; Shanjayla Connors; Ganna Chornukur; Shohreh Iravani Dickinson; Wenlong Bai; Christopher R Williams; Raoul Salup; Wui Fu
Journal:  J Cancer Sci Ther       Date:  2012-01-10

3.  Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists.

Authors:  Kasem Nithipatikom; Daniel M Brody; Alan T Tang; Vijaya L Manthati; John R Falck; Carol L Williams; William B Campbell
Journal:  Cancer Sci       Date:  2010-08-27       Impact factor: 6.716

4.  A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.

Authors:  Nagi B Kumar; Jeffrey P Krischer; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Raoul Salup; Lovellen Kang; Ping Xu; Julio Pow-Sang
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

5.  Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3.

Authors:  Mengqian Chen; Ya-Yuan Fu; Chen-Yong Lin; Li-Mei Chen; Karl X Chai
Journal:  Biochim Biophys Acta       Date:  2007-05-01

6.  The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells.

Authors:  Mengqian Chen; Li-Mei Chen; Chen-Yong Lin; Karl X Chai
Journal:  Biochim Biophys Acta       Date:  2007-11-12

7.  Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention.

Authors:  Nagi Kumar; Ganna Chornokur
Journal:  Transl Med (Sunnyvale)       Date:  2012-12-31

8.  A phase II randomized clinical trial using aglycone isoflavones to treat patients with localized prostate cancer in the pre-surgical period prior to radical prostatectomy.

Authors:  Nagi B Kumar; Julio Pow-Sang; Philippe Spiess; Shohreh Dickinson; Michael J Schell
Journal:  Oncotarget       Date:  2020-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.